Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
4.000
-0.040 (-0.99%)
At close: Jun 18, 2026, 4:00 PM EDT
3.980
-0.020 (-0.50%)
After-hours: Jun 18, 2026, 7:35 PM EDT
Bicycle Therapeutics Revenue
Bicycle Therapeutics had revenue of $887.00K in the quarter ending March 31, 2026, a decrease of -91.11%. This brings the company's revenue in the last twelve months to $63.50M, up 146.85% year-over-year. In the year 2025, Bicycle Therapeutics had annual revenue of $72.59M with 105.77% growth.
Revenue (ttm)
$63.50M
Revenue Growth
+146.85%
P/S Ratio
4.40
Revenue / Employee
$220,472
Employees
288
Market Cap
279.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.59M | 37.31M | 105.77% |
| Dec 31, 2024 | 35.28M | 8.30M | 30.76% |
| Dec 31, 2023 | 26.98M | 12.51M | 86.52% |
| Dec 31, 2022 | 14.46M | 2.77M | 23.65% |
| Dec 31, 2021 | 11.70M | 1.31M | 12.58% |
| Dec 31, 2020 | 10.39M | -3.41M | -24.72% |
| Dec 31, 2019 | 13.80M | 6.67M | 93.40% |
| Dec 31, 2018 | 7.14M | 5.08M | 246.41% |
| Dec 31, 2017 | 2.06M | - | - |
| Dec 31, 2016 | 0 | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| OmniAb | 28.94M |
| Lineage Cell Therapeutics | 14.78M |
| Surrozen | 7.49M |
| SAB Biotherapeutics | 114.70K |
| Inhibikase Therapeutics | 1.00 |
BCYC News
- 4 weeks ago - Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting - Business Wire
- 7 weeks ago - Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies - TheFly
- 7 weeks ago - Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c) - TheFly
- 7 weeks ago - Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Business Wire
- 7 weeks ago - Bicycle Therapeutics Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Bicycle Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Bicycle Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting - Business Wire